Oleg V. Leonov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oleg V. Leonov has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- A. O. Leonova
Omsk Clinical Oncological Dispensary
12 shared publications - E. I. Kopyltsov
Clinical Oncology Dispensary
10 shared publications - I. A. Sikhvardt
Omsk Clinical Oncological Dispensary
8 shared publications - Yu. N. Yurgel
Omsk Clinical Oncological Dispensary
8 shared publications - Maksim P. Salamakhin
Omsk Regional Clinical Oncology Dispensary
7 shared publications - Boris Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia
6 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 137-152
Evaluation of the Results of Intraoperative Elimination of Rectal Wall Integrity Violation after Prostatectomy with the Formation of Fascial Duplication in Patients with Prostate Cancer: A Review of Clinical Practice in Two Russian Institutions
Introduction . An intraoperative complication of prostatectomy is injury to the rectal wall. Purpose of the work is to analyze the intraoperative management of rectal wall injuries occurring during prostatectomy. Materials and Methods. A study conducted involving 36 patients who sustained a rectal wall injury during prostatectomy, divided into two groups. Group I consisted of 30 patients in whom two-layer intestinal suture used. Group II consisted of 6 patients in whom an intestinal suture combined with a fascial duplicature. Results . Patients underwent prostatectomy with lymph node dissection. In Group I, 22 complications (73.3 %) classified Clavien-Dindo grade III were recorded, compared to 0 % in Group II. The use of a fascial duplicature in Group II increase operative time (p = 0.234) or blood loss (p = 0.340). There no significant difference in preoperative length of stay (p = 0.312), while total duration of hospitalization was half as long in Group II compared to Group I (p = 0.005). Following disease progression anticancer treatment required in 46.8 % (n = 14) of patients in Group I and 16.6 % (n = 1) of patients in Group II (p > 0.05). Follow-up, 20 men from Group I remained alive, while 8 deaths recorded. Causes of death malignant neoplasms (62.5 %) and cardiovascular diseases (37.5 %). Prostate cancer cause of death in 50.0 % (n = 4) deceased men. No deaths observed in group II. Conclusion . Fascial duplication demonstrated an absence of postoperative complications, with statistically significant reduction length of hospital stay and an improvement in both early and long-term outcomes.
- 2 November 2026
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (5) , 137-152
Open AccessEvaluation of the Results of Intraoperative Elimination of Rectal Wall Integrity Violation after Prostatectomy with the Formation of Fascial Duplication in Patients with Prostate Cancer: A Review of Clinical Practice in Two Russian Institutions
Introduction . An intraoperative complication of prostatectomy is injury to the rectal wall. Purpose of the work is to analyze the intraoperative management of rectal wall injuries occurring during prostatectomy. Materials and Methods. A study conducted involving 36 patients who sustained a rectal wall injury during prostatectomy, divided into two groups. Group I consisted of 30 patients in whom two-layer intestinal suture used. Group II consisted of 6 patients in whom an intestinal suture combined with a fascial duplicature. Results . Patients underwent prostatectomy with lymph node dissection. In Group I, 22 complications (73.3 %) classified Clavien-Dindo grade III were recorded, compared to 0 % in Group II. The use of a fascial duplicature in Group II increase operative time (p = 0.234) or blood loss (p = 0.340). There no significant difference in preoperative length of stay (p = 0.312), while total duration of hospitalization was half as long in Group II compared to Group I (p = 0.005). Following disease progression anticancer treatment required in 46.8 % (n = 14) of patients in Group I and 16.6 % (n = 1) of patients in Group II (p > 0.05). Follow-up, 20 men from Group I remained alive, while 8 deaths recorded. Causes of death malignant neoplasms (62.5 %) and cardiovascular diseases (37.5 %). Prostate cancer cause of death in 50.0 % (n = 4) deceased men. No deaths observed in group II. Conclusion . Fascial duplication demonstrated an absence of postoperative complications, with statistically significant reduction length of hospital stay and an improvement in both early and long-term outcomes.
- Open Access
- 10 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2490-2495
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma
The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692 ) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600–mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This final analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months). The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]). The safety findings were consistent with the known safety profile for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone in patients with BRAF V600–mutant metastatic melanoma.
- 10 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26) , 2490-2495
Open AccessCOMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma
The COMBI-I trial (ClinicalTrials.gov identifier: NCT02967692 ) evaluating spartalizumab plus dabrafenib and trametinib (sparta-DabTram, n = 267) versus placebo plus dabrafenib and trametinib (placebo-DabTram, n = 265) for BRAF V600–mutant unresectable or metastatic melanoma failed to reach its primary end point of progression-free survival at 24 months. This final analysis reports overall survival (OS) during at least 5 years of extended follow-up. At the end of the trial (August 21, 2024), the median duration of follow-up was 76.9 months (range, 73.7-83.3 months). The median OS was 61.5 months (95% CI, 41.6 to not evaluable) for the sparta-DabTram arm and 41.6 months (95% CI, 30.6 to 56.9) for the placebo-DabTram arm (hazard ratio, 0.760 [95% CI, 0.598 to 0.966]). The safety findings were consistent with the known safety profile for sparta-DabTram. The most common treatment-related adverse event (TRAE) was pyrexia (65.9% v 46.2%, respectively, in the two study arms). Grade ≥3 TRAEs were reported in 57.3% and 36.7% of patients in the two arms, respectively. The combination of sparta-DabTram appears to improve OS compared with dabrafenib and trametinib alone in patients with BRAF V600–mutant metastatic melanoma.
- Open Access
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 77-85
Intraoperative and perioperative rectal wall integrity disruptions after prostatectomy for prostate cancer in two clinical centers: a review of treatment methods, outcomes, follow-up, and oncologic outcomes
Objective : to analyze clinical data from patients with rectal wall injury after prostatectomy, evaluate long-term surgical and oncologic outcomes, and assess the effectiveness of treatment methods. Material and Methods. A retrospective analysis of 34 patients with prostate cancer with rectal wall injury was conducted. Results. Biochemical recurrence was diagnosed in 16 men (47.1 %) with a median of 19.4 months and a median PsA of 0.8 ng/ml. local recurrence was diagnosed in 3 patients (8.8 %) after 3.9 months, 36.0 months and 80.7 months with PsA values of 0.46 ng/ml, 1.275 ng/ml and 5.24 ng/ml, respectively. Generalization of prostate cancer was confirmed in 10 men (29.4 %) with a median of 50.3 months and a median PsA of 18.7 ng/ml. Hormonal resistance of prostate cancer developed in 4 patients (11.8 %). The median follow-up of patients was 85.1 months. One-year mortality was 2.9 %. three patients were lost to follow-up after 12 months, 1.5 years, and 4 years without progression of malignant neoplasms. ten deaths were confirmed from malignant neoplasms (n=6), circulatory diseases (n=3), and unlawful acts committed against the patient (n=1). at the time of follow-up, 21 patients (67.7 %) were alive, of whom 12 (57.1 %) showed no signs of prostate cancer progression. Conclusion. in case of intraoperative and perioperative disruption of the integrity of the rectal wall after prostatectomy, restoration of the rectal defect or long-term carriage of urinary and/or intestinal stomas, possibly lifelong, does not affect the course of the tumor process and is not a direct cause of a reduction in life expectancy in men.
- 11 July 2026
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 25 (3) , 77-85
Open AccessIntraoperative and perioperative rectal wall integrity disruptions after prostatectomy for prostate cancer in two clinical centers: a review of treatment methods, outcomes, follow-up, and oncologic outcomes
Objective : to analyze clinical data from patients with rectal wall injury after prostatectomy, evaluate long-term surgical and oncologic outcomes, and assess the effectiveness of treatment methods. Material and Methods. A retrospective analysis of 34 patients with prostate cancer with rectal wall injury was conducted. Results. Biochemical recurrence was diagnosed in 16 men (47.1 %) with a median of 19.4 months and a median PsA of 0.8 ng/ml. local recurrence was diagnosed in 3 patients (8.8 %) after 3.9 months, 36.0 months and 80.7 months with PsA values of 0.46 ng/ml, 1.275 ng/ml and 5.24 ng/ml, respectively. Generalization of prostate cancer was confirmed in 10 men (29.4 %) with a median of 50.3 months and a median PsA of 18.7 ng/ml. Hormonal resistance of prostate cancer developed in 4 patients (11.8 %). The median follow-up of patients was 85.1 months. One-year mortality was 2.9 %. three patients were lost to follow-up after 12 months, 1.5 years, and 4 years without progression of malignant neoplasms. ten deaths were confirmed from malignant neoplasms (n=6), circulatory diseases (n=3), and unlawful acts committed against the patient (n=1). at the time of follow-up, 21 patients (67.7 %) were alive, of whom 12 (57.1 %) showed no signs of prostate cancer progression. Conclusion. in case of intraoperative and perioperative disruption of the integrity of the rectal wall after prostatectomy, restoration of the rectal defect or long-term carriage of urinary and/or intestinal stomas, possibly lifelong, does not affect the course of the tumor process and is not a direct cause of a reduction in life expectancy in men.
- Open Access
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 88-98
Optimal timing of adjuvant chemotherapy initiation in colon cancer patients: real-world clinical practice data
Aim. To determine the optimal timing of adjuvant chemotherapy (ACT) initiation based on real-world clinical practice data and to assess factors influencing timely ACT initiation in patients with colon cancer (CC). Materials and methods. This study is a single-center retrospective cohort analysis. Patients with CC who received ACT between 2015 and 2023 were included. Uni- and multivariate analyses of factors affecting ACT initiation timing were performed. The threshold value for ACT initiation timing in relation to overall survival (OS) and recurrence-free survival (RFS) was evaluated using area under the curve (AUC) analysis. The frequency of completing more than 3 months of ACT depending on the surgical approach was also analyzed. Results. During the study period, 871 patients received ACT. A 6-week period was established as the threshold for CC progression risk. Five-year OS was 66.4 % in the group of patients who started ACT more than 6 weeks after surgery, and 81.5 % in the group who started treatment within 6 weeks of surgery. The differences in OS were significant (hazard ratio (HR) 0.532; 95 % confidence interval (CI) 0.360–0.787; p = 0.002). Significant differences were also found in 5-year RFS (HR 0.637; 95 % CI 0.447–0.908; p = 0.013): 61.8 % in the group starting ACT more than 6 weeks after surgery and 72.4 % with earlier initiation. Multivariate analysis showed that only the absence of postoperative complications influenced the likelihood of starting ACT within 6 weeks (HR 0.365; 95 % CI 0.140–0.955; p = 0.040). Conclusion. Optimal ACT initiation timing may be shorter than 8 weeks in real-world clinical practice. Minimally invasive surgery may improve patient adherence to the ACT regimen.
- 20 June 2026
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 16 (2) , 88-98
Open AccessOptimal timing of adjuvant chemotherapy initiation in colon cancer patients: real-world clinical practice data
Aim. To determine the optimal timing of adjuvant chemotherapy (ACT) initiation based on real-world clinical practice data and to assess factors influencing timely ACT initiation in patients with colon cancer (CC). Materials and methods. This study is a single-center retrospective cohort analysis. Patients with CC who received ACT between 2015 and 2023 were included. Uni- and multivariate analyses of factors affecting ACT initiation timing were performed. The threshold value for ACT initiation timing in relation to overall survival (OS) and recurrence-free survival (RFS) was evaluated using area under the curve (AUC) analysis. The frequency of completing more than 3 months of ACT depending on the surgical approach was also analyzed. Results. During the study period, 871 patients received ACT. A 6-week period was established as the threshold for CC progression risk. Five-year OS was 66.4 % in the group of patients who started ACT more than 6 weeks after surgery, and 81.5 % in the group who started treatment within 6 weeks of surgery. The differences in OS were significant (hazard ratio (HR) 0.532; 95 % confidence interval (CI) 0.360–0.787; p = 0.002). Significant differences were also found in 5-year RFS (HR 0.637; 95 % CI 0.447–0.908; p = 0.013): 61.8 % in the group starting ACT more than 6 weeks after surgery and 72.4 % with earlier initiation. Multivariate analysis showed that only the absence of postoperative complications influenced the likelihood of starting ACT within 6 weeks (HR 0.365; 95 % CI 0.140–0.955; p = 0.040). Conclusion. Optimal ACT initiation timing may be shorter than 8 weeks in real-world clinical practice. Minimally invasive surgery may improve patient adherence to the ACT regimen.
- Open Access
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 76-87
Efficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia
Background. The decade-long use of checkpoint inhibitors in real-world clinical practice in Russia allowed to treat hundreds of patients with urothelial malignancies. The AURORA-RU Phase IV observational Russian study was initiated to evaluate the efficacy of atezolizumab in patients with urothelial carcinoma resistant to platinum-based chemotherapy. This article is based on an analysis conducted at a median follow-up of 60.7 months and provides data on treatment efficacy in Russian patients receiving second-line and subsequent lines of systemic therapy. Aim. To evaluate the clinical efficacy of atezolizumab monotherapy in patients with urothelial carcinoma of the upper and lower urinary tract progressing on platinum-based chemotherapy in a real-world clinical setting. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included subgroup analyses of efficacy based on the line of therapy (including the subgroup with early progression after neo/adjuvant chemotherapy [NACT/ACT]), age cohort, metastatic sites, and primary tumor location (bladder vs. upper urinary tract). Materials and methods. The study included data from 152 patients with verified muscle-invasive locally advanced and metastatic urothelial carcinoma who received PD-L1 inhibitor (atezolizumab) monotherapy across 13 centers in the Russian Federation between 2019 and 2025. Atezolizumab treatment was administered to patients who progressed on platinum-based chemotherapy. More than half of the patients (55.9 %) were over 65 years of age. The cohort consisted of 75.0 % men and 25.0 % women. The majority of patients (78.3 %) had a primary tumor located in the bladder. PD-L1 inhibitor therapy was administered as second-line treatment in 57.9 % of cases, while one in five patients (21.7 %) received third-line treatment. In 86.8 % of cases, treatment was administered without prior assessment of PD-L1 expression levels. Results. In the overall cohort, the median PFS reached 5.5 months, with 36-month and 48-month PFS rates of 15.9 % and 9.9 %, respectively. The median OS was 12.0 months; 21.9 % of patients survived 3 years, and 14.3 % of patients remained under observation for five years. In patients transitioning to immuno-oncology treatment after rapid progression following NACT/ACT, the median OS was 17.4 months. The median OS for second-line therapy was two-fold higher than for third-line therapy: 13.9 months versus 6.1 months. High treatment efficacy was noted in patients over 70 years of age (median PFS of 8.7 months; median OS of 14.9 months). Conclusion. In real-world practice, PFS and OS rates were comparable to those reported in registration trials and other real-world evidence studies. The lack of PD-L1 expression testing generally did not affect the efficacy of immuno-oncology therapy in patients with urothelial carcinoma.
- 27 February 2026
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (4) , 76-87
Open AccessEfficacy of atezolizumab in patients resistant to platinum-based chemotherapy. Results of the AURORA-RU Study: Atezolizumab in UROthelial cancer: Real-world Analysis of RUssia
Background. The decade-long use of checkpoint inhibitors in real-world clinical practice in Russia allowed to treat hundreds of patients with urothelial malignancies. The AURORA-RU Phase IV observational Russian study was initiated to evaluate the efficacy of atezolizumab in patients with urothelial carcinoma resistant to platinum-based chemotherapy. This article is based on an analysis conducted at a median follow-up of 60.7 months and provides data on treatment efficacy in Russian patients receiving second-line and subsequent lines of systemic therapy. Aim. To evaluate the clinical efficacy of atezolizumab monotherapy in patients with urothelial carcinoma of the upper and lower urinary tract progressing on platinum-based chemotherapy in a real-world clinical setting. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included subgroup analyses of efficacy based on the line of therapy (including the subgroup with early progression after neo/adjuvant chemotherapy [NACT/ACT]), age cohort, metastatic sites, and primary tumor location (bladder vs. upper urinary tract). Materials and methods. The study included data from 152 patients with verified muscle-invasive locally advanced and metastatic urothelial carcinoma who received PD-L1 inhibitor (atezolizumab) monotherapy across 13 centers in the Russian Federation between 2019 and 2025. Atezolizumab treatment was administered to patients who progressed on platinum-based chemotherapy. More than half of the patients (55.9 %) were over 65 years of age. The cohort consisted of 75.0 % men and 25.0 % women. The majority of patients (78.3 %) had a primary tumor located in the bladder. PD-L1 inhibitor therapy was administered as second-line treatment in 57.9 % of cases, while one in five patients (21.7 %) received third-line treatment. In 86.8 % of cases, treatment was administered without prior assessment of PD-L1 expression levels. Results. In the overall cohort, the median PFS reached 5.5 months, with 36-month and 48-month PFS rates of 15.9 % and 9.9 %, respectively. The median OS was 12.0 months; 21.9 % of patients survived 3 years, and 14.3 % of patients remained under observation for five years. In patients transitioning to immuno-oncology treatment after rapid progression following NACT/ACT, the median OS was 17.4 months. The median OS for second-line therapy was two-fold higher than for third-line therapy: 13.9 months versus 6.1 months. High treatment efficacy was noted in patients over 70 years of age (median PFS of 8.7 months; median OS of 14.9 months). Conclusion. In real-world practice, PFS and OS rates were comparable to those reported in registration trials and other real-world evidence studies. The lack of PD-L1 expression testing generally did not affect the efficacy of immuno-oncology therapy in patients with urothelial carcinoma.
- 1 January 2026
- Published by FSBEI HE NSMU MOH Russia in Sibirskij medicinskij vestnik
- Vol. 10 (2)
MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF CHANGES IN PELVIC ORGANS AFTER THE FORMATION OF FASCIAL DUPLICATION COVERING THE INTRAOPERATIVELY DETECTED COMPROMISED INTEGRITY OF THE RECTAL WALL DURING PROSTATECTOMY
Introduction. Modern imaging techniques for internal organs are used in diagnosis, evaluation of treatment effectiveness, and subsequent follow-up of patients with prostate cancer. Magnetic resonance imaging, providing detailed visualization of soft tissue, is becoming the most common and highly effective imaging method for prostate cancer. Aim of the research. To present the experience of using magnetic resonance imaging to assess changes in the pelvic organs within a year after a single-stage reconstructive surgery using local tissues in case of a defect integrity of the rectal wall during prostatectomy. Materials and methods. A clinical case of diagnosis and surgical treatment of a patient with prostate cancer is described. A 2.5 cm rectal wall defect was detected intraoperatively during prostatectomy. The rectal defect was sutured with a two-row interrupted intestinal suture and additionally covered with pelvic fascia layers using the proposed original technique (Patent No. 2735904 dated November 10, 2020, "Method for Forming a Fascial Duplication to Repair an Anterior Rectal Wall Defect after Prostatectomy"). Intestinal stoma formation and/or external drainage of the lower urinary tract were not performed. The surgery duration was 140 minutes, and blood loss was 150 ml. Magnetic resonance imaging of the pelvis with intravenous contrast was performed over the course of 1 year. Results. On the 14th day after surgery, the fascial duplication separating the rectal and bladder walls, was unevenly thickened to 7 mm, with soft tissue edema at the anastomosis site. Three months later, adhesions were visible in the bed of the removed prostate at the level of the vesicoureteral anastomosis and the anterior rectal wall, with contrast accumulation due to hypervascularization in the granulation tissue. Six months after prostatectomy, fibrosis was detected between the posterior bladder contour with the urethra and the anterior rectal wall, with localized wall thickening of up to 9 mm and a length of 15 mm. At the 12-month follow-up examination, no changes were observed in the postoperative scar formed between the posterior bladder wall with the urethra and the anterior rectal wall, covered by the fascial duplication; the condition was stable. Conclusion. Formation of a fascial duplication in case of compromised rectal wall integrity during prostatectomy ensures reliable and rapid healing by primary intention, which ensures optimal treatment results in the early, late and long-term periods.
- 1 January 2026
- Published by FSBEI HE NSMU MOH Russia in Sibirskij medicinskij vestnik
- Vol. 10 (2)
MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF CHANGES IN PELVIC ORGANS AFTER THE FORMATION OF FASCIAL DUPLICATION COVERING THE INTRAOPERATIVELY DETECTED COMPROMISED INTEGRITY OF THE RECTAL WALL DURING PROSTATECTOMY
Introduction. Modern imaging techniques for internal organs are used in diagnosis, evaluation of treatment effectiveness, and subsequent follow-up of patients with prostate cancer. Magnetic resonance imaging, providing detailed visualization of soft tissue, is becoming the most common and highly effective imaging method for prostate cancer. Aim of the research. To present the experience of using magnetic resonance imaging to assess changes in the pelvic organs within a year after a single-stage reconstructive surgery using local tissues in case of a defect integrity of the rectal wall during prostatectomy. Materials and methods. A clinical case of diagnosis and surgical treatment of a patient with prostate cancer is described. A 2.5 cm rectal wall defect was detected intraoperatively during prostatectomy. The rectal defect was sutured with a two-row interrupted intestinal suture and additionally covered with pelvic fascia layers using the proposed original technique (Patent No. 2735904 dated November 10, 2020, "Method for Forming a Fascial Duplication to Repair an Anterior Rectal Wall Defect after Prostatectomy"). Intestinal stoma formation and/or external drainage of the lower urinary tract were not performed. The surgery duration was 140 minutes, and blood loss was 150 ml. Magnetic resonance imaging of the pelvis with intravenous contrast was performed over the course of 1 year. Results. On the 14th day after surgery, the fascial duplication separating the rectal and bladder walls, was unevenly thickened to 7 mm, with soft tissue edema at the anastomosis site. Three months later, adhesions were visible in the bed of the removed prostate at the level of the vesicoureteral anastomosis and the anterior rectal wall, with contrast accumulation due to hypervascularization in the granulation tissue. Six months after prostatectomy, fibrosis was detected between the posterior bladder contour with the urethra and the anterior rectal wall, with localized wall thickening of up to 9 mm and a length of 15 mm. At the 12-month follow-up examination, no changes were observed in the postoperative scar formed between the posterior bladder wall with the urethra and the anterior rectal wall, covered by the fascial duplication; the condition was stable. Conclusion. Formation of a fascial duplication in case of compromised rectal wall integrity during prostatectomy ensures reliable and rapid healing by primary intention, which ensures optimal treatment results in the early, late and long-term periods.
- Open Access
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 60-68
Analysis of the learning curve for laparoscopic colon resections in a specialized regional clinic
Aim. To investigate the learning curve for laparoscopic colon resections in a specialized regional clinical setting. Materials and methods. Analysis of the data from the Omsk Regional Cancer Registry and the hospital information system of the Omsk Clinical Oncology Center from the period between 2015 and 2023 was performed. The study included patients who underwent laparoscopic colon resections for cancer. Risk-adjusted cumulative sum (RA-CUSUM) method was used to define the stages of mastering the technique. The primary outcome measure was the incidence of severe postoperative complications (Clavien–Dindo grade IIIB and above). Operative time, intraoperative blood loss, conversion rate, length of hospital stay and long-term treatment outcomes were also analyzed. Results. Data from 305 laparoscopic colon resections were included in the analysis. The proportion of laparoscopic procedures increased from 8.9 % in 2015 to 27.8 % in 2023. The learning curve analysis revealed four distinct phases of proficiency acquisition. In the 1st phase (procedures 1–30), the complication risk was 0 %. The 2nd phase (procedures 31–80) was characterized by the highest risk of severe complications at 20.00 % (95 % confidence interval 11.24–33.04). A decrease in risk was observed during the 3rd phase (procedures 81–93). The final, 4th phase (procedures 94–304) achieved consistently low complication risk of 2.84 % (95 % confidence interval 1.31–6.06). The critical point for completing the learning phase was identified at the 93rd procedure. Analysis of the learning curve for conversions revealed the peak conversion rate of 23.1 % during the recovery phase, which subsequently decreased to 2.4 % in the stability phase. The overall conversion rate for the entire series decreased from 11.1 % in 2015 to 6.0 % in 2023. Operative time and intraoperative blood loss remained stable throughout the observation period. The 5-year overall survival rate was 81.6 %, and the recurrence-free survival rate was 81.1 %. Conclusion. The implementation of laparoscopic technologies requires structured training with increase in the number of surgeons performing minimally invasive surgeries. The period of intense learning occurs between the 30th and 80th procedures, after which stable and predictable results are achieved.
- 21 December 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (4) , 60-68
Open AccessAnalysis of the learning curve for laparoscopic colon resections in a specialized regional clinic
Aim. To investigate the learning curve for laparoscopic colon resections in a specialized regional clinical setting. Materials and methods. Analysis of the data from the Omsk Regional Cancer Registry and the hospital information system of the Omsk Clinical Oncology Center from the period between 2015 and 2023 was performed. The study included patients who underwent laparoscopic colon resections for cancer. Risk-adjusted cumulative sum (RA-CUSUM) method was used to define the stages of mastering the technique. The primary outcome measure was the incidence of severe postoperative complications (Clavien–Dindo grade IIIB and above). Operative time, intraoperative blood loss, conversion rate, length of hospital stay and long-term treatment outcomes were also analyzed. Results. Data from 305 laparoscopic colon resections were included in the analysis. The proportion of laparoscopic procedures increased from 8.9 % in 2015 to 27.8 % in 2023. The learning curve analysis revealed four distinct phases of proficiency acquisition. In the 1st phase (procedures 1–30), the complication risk was 0 %. The 2nd phase (procedures 31–80) was characterized by the highest risk of severe complications at 20.00 % (95 % confidence interval 11.24–33.04). A decrease in risk was observed during the 3rd phase (procedures 81–93). The final, 4th phase (procedures 94–304) achieved consistently low complication risk of 2.84 % (95 % confidence interval 1.31–6.06). The critical point for completing the learning phase was identified at the 93rd procedure. Analysis of the learning curve for conversions revealed the peak conversion rate of 23.1 % during the recovery phase, which subsequently decreased to 2.4 % in the stability phase. The overall conversion rate for the entire series decreased from 11.1 % in 2015 to 6.0 % in 2023. Operative time and intraoperative blood loss remained stable throughout the observation period. The 5-year overall survival rate was 81.6 %, and the recurrence-free survival rate was 81.1 %. Conclusion. The implementation of laparoscopic technologies requires structured training with increase in the number of surgeons performing minimally invasive surgeries. The period of intense learning occurs between the 30th and 80th procedures, after which stable and predictable results are achieved.
- Open Access
- 16 August 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (3) , 176-181
A linear stapler-free colonic anastomosis for left colectomy: a retrospective comparative study
AIM: to evaluate early outcomes of original colon linear stapler-free anastomosis after left hemicolectomy or sigmoid resection.PATIENTS AND METHODS: a retrospective study included 98 patients, who underwent a laparoscopic left colon resection with anastomosis were included and divided in 2 groups: single stapler (study group) and double stapler (control group) anastomosis. The primary endpoint was anastomotic leakage. Secondary endpoints included surgical morbidity (Clavien-Dindo), operation time, blood loss and hospital stay.RESULTS: thirty-nine patients were included in the study group and 59 in the control group. No cases of anastomotic leakage were observed. Surgical morbidity grade IIIB or higher developed in 0 and 1 (1.7%) patients, accordingly (р = 1.0). Median hospital stay was 8 days (7; 11) and 10 days (7; 11), р = 0.19), median bloodloss 50 ml (50; 70) and 50 ml (50; 100), р = 0.8. Operation time was shorter in the main group 100 min (80; 120) and 120 min (82.5; 155), р = 0.048.CONCLUSIONS: the original anastomosis is safe.
- 16 August 2025
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 24 (3) , 176-181
Open AccessA linear stapler-free colonic anastomosis for left colectomy: a retrospective comparative study
AIM: to evaluate early outcomes of original colon linear stapler-free anastomosis after left hemicolectomy or sigmoid resection.PATIENTS AND METHODS: a retrospective study included 98 patients, who underwent a laparoscopic left colon resection with anastomosis were included and divided in 2 groups: single stapler (study group) and double stapler (control group) anastomosis. The primary endpoint was anastomotic leakage. Secondary endpoints included surgical morbidity (Clavien-Dindo), operation time, blood loss and hospital stay.RESULTS: thirty-nine patients were included in the study group and 59 in the control group. No cases of anastomotic leakage were observed. Surgical morbidity grade IIIB or higher developed in 0 and 1 (1.7%) patients, accordingly (р = 1.0). Median hospital stay was 8 days (7; 11) and 10 days (7; 11), р = 0.19), median bloodloss 50 ml (50; 70) and 50 ml (50; 100), р = 0.8. Operation time was shorter in the main group 100 min (80; 120) and 120 min (82.5; 155), р = 0.048.CONCLUSIONS: the original anastomosis is safe.
- Open Access
- 10 June 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (2) , 142-146
Comparative safety of intracorporeal versus extracorporeal anastomoses in laparoscopic right colectomy
Aim – to assess the safety of a hand-sewn intracorporeal ileo-transverse anastomosis. Material and methods. The retrospective study included patients from the Omsk Regional Cancer Registry from 2015 to 2023. It included patients with colon cancer (ICD-10 C18), who underwent a laparoscopic right colectomy. In the study group patients had hand-sewn intracorporeal anastomoses dene under an original method, terminus-terminal invagination ileo-transverse anastomosis; in the control group patients had hand-sewn ‘side-to-side’ extracorporeal anastomoses. Results. 89 patients were enrolled: 42 in the study group and 47 in the control group. No cases of anastomotic leakage were found in the study group versus 2 (4.3%) in the control group (p=0.496). Grade 3 and higher surgical morbidity was equal in both groups: 2 (4.8%) versus 5 (10.7%), p=0.550. Conclusion. The hand-sewn original intracorporeal anastomosis is safe and can be considered by experienced laparoscopic surgeons. Further study is needed for a detailed comparative analysis with established techniques.
- 10 June 2025
- Published by FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation in Science and Innovations in Medicine
- Vol. 10 (2) , 142-146
Open AccessComparative safety of intracorporeal versus extracorporeal anastomoses in laparoscopic right colectomy
Aim – to assess the safety of a hand-sewn intracorporeal ileo-transverse anastomosis. Material and methods. The retrospective study included patients from the Omsk Regional Cancer Registry from 2015 to 2023. It included patients with colon cancer (ICD-10 C18), who underwent a laparoscopic right colectomy. In the study group patients had hand-sewn intracorporeal anastomoses dene under an original method, terminus-terminal invagination ileo-transverse anastomosis; in the control group patients had hand-sewn ‘side-to-side’ extracorporeal anastomoses. Results. 89 patients were enrolled: 42 in the study group and 47 in the control group. No cases of anastomotic leakage were found in the study group versus 2 (4.3%) in the control group (p=0.496). Grade 3 and higher surgical morbidity was equal in both groups: 2 (4.8%) versus 5 (10.7%), p=0.550. Conclusion. The hand-sewn original intracorporeal anastomosis is safe and can be considered by experienced laparoscopic surgeons. Further study is needed for a detailed comparative analysis with established techniques.